Hangzhou Youhua Pharmaceutical Technology

Hangzhou Youhua Pharmaceutical Technology is a clinical-stage biopharmaceutical company focused on the development of innovative small molecule drugs for metabolic diseases and oncology. Headquartered in Hangzhou, China, the company is led by a team of industry veterans with extensive experience in global drug R&D. Its lead program, YH-201, is a potent and selective oral small molecule GLP-1 receptor agonist currently in Phase 2 clinical trials for the treatment of type 2 diabetes and obesity. Youhua aims to address significant unmet medical needs by providing effective and patient-friendly oral alternatives to existing injectable therapies. The company has successfully raised multiple rounds of financing from prominent venture capital firms to support its growing pipeline.